QSI Stock: Quantum-Si Looks to Lead the Post-Genomic Era

Genomics had its moment; now Quantum-Si [QSI] wants to lead the ‘post-genomic era’ with a machine that reads proteins one molecule at a time. 

The Branford, Connecticut-based firm pioneered single-molecule protein sequencing technology, which aims to overcome key limitations of traditional protein analysis methods by reducing instrument costs, simplifying workflows and providing deeper insights into proteins.

In October, QSI shares climbed to an 11-month high after the company announced that its next-generation protein sequencing platform, Proteus, was on track to detect all 20 standard amino acids by the end of 2026. The milestone is expected to pave the way for the platform’s commercial launch in 2027.

In this stock spotlight, we examine Quantum-Si’s latest developments, financial performance, stock market trends and the bull and bear cases for QSI shares.

Key developments

Proteus development

Throughout 2026, investor attention on Quantum-Si has centred on developments related to Proteus. Announced in November 2024, Proteus is designed to succeed the company’s existing Platinum and Platinum Pro lines of instruments and was initially expected to launch by the end of 2026.

Proteus also dominated management focus, with CEO Jeffrey Hawkins revealing in the Q2 2026 earnings callthat the three corporate priorities for 2026 were completing Proteus development, building customer awareness for its launch, and preserving its financial runway to fund the platform’s development and commercialisation.

However, in August, Quantum-Si postponed the commercial launch of Proteus to Q2 2027 after testing revealed the need for an additional design cycle to reduce manufacturing risk and improve product readiness.

Since then, product development updates have been more positive. In late September, the company presented interim results at the 2026 World HUPO Congress in Singapore showing that Proteus could deliver approximately 30 times as many sequencing alignments per instrument run than Platinum Pro, with a false discovery rate that is 4.8 times lower.

Quantum-Si said the improvements in sequencing scale, signal quality, conversion efficiency and accuracy positioned Proteus to transform single-molecule protein sequencing.

On 8 October, the company followed up by announcing that Proteus had demonstrated detection of 19 amino acids. Detection of all 20 amino acids was expected by the end of 2026, management added.

Financial runway and monetisation

Beyond Proteus development, Quantum-Si has focused on preserving its financial runway. In August, the company announced a 20% workforce reduction, which was expected to generate $12m in annualised operating expense savings.

Building customer awareness ahead of the Proteus launch has also been a priority, with Quantum-Si conducting roadshows across the US and Europe. Hawkins underscored the importance of these pre-launch efforts, noting that “Proteus is expected to far exceed Platinum Pro’s capabilities.”

Management’s efforts to build the foundation for Proteus’ success have resulted in subdued near-term revenue for the company due to “deliberate commercial decisions”. These initiatives included offering free placements of its Platinum instruments and upgrade credits for Platinum Pro units to provide existing customers with a clear path to Proteus.

Expectations for Proteus monetisation remain high. During the Q2 2026 earnings call, management revealed that Quantum-Si was working with multiple customers to explore protein sequencing applications in agriculture, pathogen detection and viral protein surveillance.

“We believe the non-human proteomics market opportunity for Proteus is substantial, at more than $4bn annually,” Hawkins noted during the earnings call, adding that the size of the opportunity may grow as Quantum-Si’s understanding of the market develops.

Hawkins also highlighted opportunities in gene therapy, noting that more than 150 biotechnology and pharmaceutical companies were developing therapies using adeno-associated viruses (AAVs). In November 2025, Quantum-Si completed a study demonstrating the use of next-generation protein sequencing to identify AAV8 and AAV9 capsid proteins.

“To date, we have identified and qualified more than 250 unique institutions with stated interest in Proteus and the capabilities we are aiming to deliver,” said Hawkins in August.

QSI jumps to 11-month high

QSI share price has risen by 26.36% year-to-date to $1.39, as of the 14 October close, on the back of positive Proteus development updates. In comparison, the US benchmark S&P 500 index was up about 12.76% during the same period.

On 9 October, QSI stock surged as much as 36% to $1.66, its highest since November 2025.

Over the past year, however, the Quantum-Si share price has slumped by 33.17%.

Swayampakula Ramakanth, senior healthcare analyst at H.C. Wainwright, rated QSI stock a ‘buy’ with a price target of $4.00, implying a potential upside of 187.8% from its current price of $1.39.

Financial health: QSI continues to post losses

Quantum-Si is an early-stage technology company that has incurred losses since it was formed in 2013. In fiscal 2025, the company posted a net loss of $101.34m, compared with a net loss of $101.01m in 2024.

The company commercialised its first product, Platinum, in 2024, before launching Platinum Pro in 2025. In fiscal 2025, total revenue was $2.44m, compared with $3.06m in 2024.

In H1 2026, total revenue was about $602,000, down from $1.43m a year ago. H1 net loss was $45.21m versus $48.03m a year ago.

The company has raised capital primarily through equity financing. In September 2025, Quantum-Si signed an at-the-market equity offering programme with Leerink Partners, allowing it to sell shares worth up to $100m.

At the end of June 2026, Quantum-Si had $169.9m in cash and cash equivalents, giving it a runway until Q4 2028.

For fiscal 2026, QSI expects total cash usage to be $93m or less. 2026 revenue is expected to come in at about $1m.

Comparing fundamentals: QSI vs A vs WAT

Agilent Technologies [A] and Waters [WAT] are life sciences technology companies that specialise in liquid chromatography and mass spectrometry instrument platforms, which are used for drug discovery, clinical diagnostics, research and environmental analysis, among other uses.

Liquid chromatography and mass spectrometry are legacy techniques that have been the dominant tool for protein analysis. According to Quantum-Si, these techniques are complex and lengthy, and require extensive data analysis and expensive equipment. Mass spectrometry instruments can cost over $1m, according to Quantum-Si. The company is looking to undercut market incumbents by offering its upcoming Proteus platform at $425,000.

Source: Yahoo Finance

QSI stock: The investment case

The bull case for Quantum-Si: Leading post-genomic era research

Quantum-Si expects its next-generation protein sequencing technology to power the “post-genomic era”, where researchers move from DNA and RNA to focus on proteins in drug development, scientific research, disease detection and personalised medicine.

Beyond human proteomics, Quantum-Si sees opportunities in agriculture, pathogen detection and viral surveillance, estimating an annual market opportunity exceeding $4bn. According to management, more than 250 institutions have expressed interest in the upcoming Proteus platform, which is said to be cheaper and easier to use than legacy protein analysis technologies.

The bear case for Quantum-Si: Monetisation challenge

The development of Proteus carries execution risks, as highlighted by the delay in its commercial launch from 2026 to 2027. Moreover, Quantum-Si’s protein sequencing platforms are currently intended for research use only. The company would need regulatory clearance or approval from the US Food and Drug Administration to market its instruments for clinical diagnostic applications.

Investor concerns over Quantum-Si’s cash runway, limited revenue generation and continued losses could weigh on its share price until Proteus is commercialised and begins generating meaningful revenue.

Conclusion

Quantum-Si’s investment outlook hinges on the successful commercialisation of Proteus in 2027. The next update that investors will be looking out for is the successful detection of all 20 amino acids by Proteus.

While Quantum-Si’s cash reserves provide time to monetise Proteus, continued losses, commercialisation risks and potential shareholder dilution remain key concerns.